Myositis and myopathiesMyositis: an update on pathogenesisChristopher-Stine, Lisaa; Plotz, Paul Hb Author Information aInstructor in Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA and bChief, Arthritis and Rheumatism Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA Correspondence to Paul H. Plotz, Chief, Arthritis and Rheumatism Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Clinical Center 9N244, Bethesda, MD 20892-1820, USA Tel: 301 496 9904; fax: 301 402 0012; e-mail: [email protected] Current Opinion in Rheumatology: November 2004 - Volume 16 - Issue 6 - p 700-706 doi: 10.1097/01.bor.0000141925.21941.d8 Buy Metrics Abstract Purpose of review The etiology and much about the pathogenesis of the inflammatory myopathies remain a mystery. In this review, we investigate recent research efforts to understand the pathogenesis of the diverse entities of polymyositis (PM), dermatomyositis (DM), and inclusion body myositis (IBM), diseases that result from interactions between environmental risk factors and genetic susceptibility. Recent findings Over the past year, there has been considerable progress toward better understanding of IBM, with relatively few developments toward understanding PM and DM. Although these diseases may share some common clinical phenotypic and serologic components, they differ on a molecular and cellular level. Summary The need for definitive, safer therapies in these diseases makes vital the search for defining detailed pathogenesis of inflammation and muscle fiber damage at the molecular level. © 2004 Lippincott Williams & Wilkins, Inc.